Ophthotech Corporation (NASDAQ:OPHT): $0.16 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 1.12. The value of trades done on upticks was $1.54 million, whereas, trades done on downticks were valued at $1.38 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.01 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.01 million. Ophthotech Corporation (NASDAQ:OPHT) fell $0.39 traded at $51.29, a change of -0.75% over the previous day. The stock is -1.35% for the week.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Ophthotech Corp., Bolte Axel, had purchased 3,500 shares in a transaction dated on June 3, 2016. The transaction was executed at $56.97 per share with total amount equaling $199,395. Currently the company Insiders own 12.2% of Ophthotech Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.92% . Institutional Investors own 90.6% of Ophthotech Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -26.65%.
The company shares have dropped -0.50% from its 1 Year high price. On Dec 30, 2015, the shares registered one year high at $80.00 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $51.96 and the 200 Day Moving Average price is recorded at $52.72. Ophthotech Corporation (NASDAQ:OPHT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $52.41 and $50.84 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $53.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $51.98, notching a gain of 0.58% for the day. The total traded volume was 379,330 . The stock had closed at $51.68 on the previous day.
Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.